Optimization of humanized IgGs in glycoengineered Pichia pastoris

Nature Biotechnology

Volumn 24, Issue 2, 2006, Pages 210-215

  Li, Huijuan ^a   Sethuraman, Natarajan ^a   Stadheim, Terrance A ^a   Zha, Dongxing ^a   Prinz, Bianka ^a   Ballew, Nicole ^a   Bobrowicz, Piotr ^a   Choi, Byung Kwon ^a   Cook, W James ^a   Cukan, Michael ^a   Houston Cummings, Nga Rewa ^a   Davidson, Robert ^a   Gong, Bing ^a   Hamilton, Stephen R ^a   Hoopes, Jack P ^b   Jiang, Youwei ^a   Kim, Nam ^a   Mansfield, Renee ^a   Nett, Juergen H ^a   Rios, Sandra ^a   Strawbridge, Rendall ^b   Wildt, Stefan ^a   Gerngross, Tillman U ^c,d   more..

^a GlycoFi Incorporated   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c DARTMOUTH COLLEGE   (United States)

^d Dartmouth College   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; CELLS; HUMAN REHABILITATION ENGINEERING; IMMUNOLOGY; OPTIMIZATION; PROTEINS;

GLYCOENGINEERED PICHIA PASTORIS; GLYCOSYLATION STRUCTURES; MONOCLONAL ANTIBODIES (MABS);

DRUG PRODUCTS;

ANTIBODY; GLYCAN; IMMUNOGLOBULIN G; RECOMBINANT ANTIBODY;

ARTICLE; BIOENGINEERING; GLYCOSYLATION; NONHUMAN; PICHIA PASTORIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; YEAST;

ANTIBODIES, MONOCLONAL; GENETIC ENHANCEMENT; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; PICHIA; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

MAMMALIA; PICHIA PASTORIS;

EID: 32344449790     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1178     Document Type: Article

References (18)

1. Weiner, L.M. & Carter, P. Tunable antibodies. Nat. Biotechnol. 23, 556-557 (2005).
2. Rothman, R.J., Perussia, B., Herlyn, D. & Warren, L. Antibody-dependent cytotoxicity mediated by natural killer cells is enhanced by castanospermine-induced alterations of IgG glycosylation. Mol. Immunol. 26, 1113-1123 (1989).
3. Lifely, M.R., Hale, C., Boyce, S., Keen, M.J. & Phillips, J. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 5, 813-822 (1995).
4. Umaña, P. et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17, 176-180 (1999).
5. Shields, R.L. et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellulartoxicity. J. Biol. Chem. 277, 26733-26740 (2002).
6. Shinkawa, T. et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytoxicity. J. Biol. Chem. 278, 3466-3473 (2003).
7. Clynes, R.A., Towers, T.L., Presta, L.G. & Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6, 443-446 (2000).
8. Cartron, G. et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99, 754-758 (2002).
9. Choi, B.-K. et al. Use of combinatorial genetic libraries to humanized N-linked glycosylation in the yeast Pichia pastoris. Proc. Natl. Acad. Sci. USA 100, 5022-5027 (2003).
10. Hamilton, S. et al. Production of complex human glycoproteins in yeast. Science 301, 1244-1246 (2003).
11. Bobrowicz, P. et al. Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: Production of complex humanized glycoproteins with terminal galactose. Glycobiology 14, 757-766 (2004).
12. Gerngross, T.U. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat. Biotechnol. 22, 1409-1414 (2004).
13. Wright, A. et al. In vivo trafficking and catabolism of IgG1 with Fc associated carbohydrates of differing structure. Glycobiology 10, 1347-1355 (2000).
14. Wright, A. & Morrison, S.L. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J. Immunol. 160, 3393-3402 (1998).
15. Anderson, D.R. et al. Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. US Patent No. 6,682,734 (1995).
16. Hong, K. et al. Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD20. J. Immunol. Methods 294, 189-197 (2004).
17. Shields, R.L. et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII and FcRn and design of IgG1 variants with improved binding to the FcgR. J. Biol. Chem. 276, 6591-6604 (2001).
18. Vugmeyster, Y. & Howell, K. Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG. Int. Immunopharmacol. 4, 1117-1124 (2004).